TET2 as a new diagnostic and pronostic marker in hematopoietic neoplasms
US9297046B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 21, 2012 |
| Grant date | Mar 29, 2016 |
| Priority date | — |
| Expiry date | Jun 21, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.